Lilly's Solanezumab Fails In Alzheimer's Prevention Trial
9/3 02:41
(RTTNews) - Eli Lilly and Co. (LLY), in an update on A4 Study of Solanezumab for preclinical Alzheimer's Disease, said Wednesday that the drug did not slow the progression of cognitive decline due to Alzheimer's disease (AD) pathology when initiated in individuals with amyloid pl...